Benzinga | Mar 11, 2021 08:02AM EST

aTyr Pharma Announces Poster Presentations At Upcoming American Association For Cancer Research Annual Meeting Apr. 10-15 And May 17-21

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10 -- 15 and May 17 -- 21.



Details of the poster presentations are as follows:

Title: The Neuropilin-2 targeting antibody ATYR2810 inhibits non-small cell lung cancer tumor growth in monotherapy and combination therapy

Authors: Alison G. Barber, Zhiwen Xu, Justin Rahman, Hira Lal Goel, Arthur M. Mercurio, Christoph Burkart, Leslie A. Nangle. aTyr Pharma, San Diego, CA, UMass Medical School, Boston, MA.

Abstract Number: 5247

Session Category: Tumor Biology

Session Title: Human-in-Mouse Models of Human Cancer

Poster Number: LB234

Permanent Abstract Number: LB234

Date and Time: April 10 -- 15 and May 17 -- 21 (9:00AM -- 6:00PM ET)

Title: A domain-specific antibody to NRP2 down-regulated epithelial-mesenchymal transition genes and enhanced efficacy of standard-of-care therapeutics for aggressive breast cancer

Authors: Zhiwen Xu, Christoph Burkart, Hira Lal Goel, Justin Rahman, Clara Polizzi, Matt Seikkula, Luke Burman, Arthur M. Mercurio, Leslie A. Nangle. aTyr Pharma, San Diego, CA, UMass Medical School, Boston, MA.

Abstract Number: 5316

Session Category: Experimental and Molecular Therapeutics

Session Title: Biological Therapeutic Agents

Poster Number: LB095

Permanent Abstract Number: LB095

Date and Time: April 10 -- 15 and May 17 -- 21 (9:00AM -- 6:00PM ET)